VYKAT XR Drug Patent Profile

When do Vykat Xr patents expire, and what generic alternatives are available?

Vykat Xr is a drug marketed by Soleno Therap and is included in one NDA. There are six patents protecting this drug.

This drug has seventy-nine patent family members in twenty-two countries.

The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diazoxide choline profile page.

DrugPatentWatch^® Generic Entry Outlook for Vykat Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VYKAT XR

International Patents:	79
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in VYKAT XR?	VYKAT XR excipients list
DailyMed Link:	VYKAT XR at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYKAT XR

Constraining patent/regulatory exclusivity:

TREATMENT OF HYPERPHAGIA IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH PRADER-WILLI SYNDROME (PWS)

NDA:

216665

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VYKAT XR

VYKAT XR is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF HYPERPHAGIA IN ADULTS AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER WITH PRADER-WILLI SYNDROME (PWS).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Soleno Therap	VYKAT XR	diazoxide choline	TABLET, EXTENDED RELEASE;ORAL	216665-001	Mar 26, 2025		RX	Yes	No	12,343,348
Soleno Therap	VYKAT XR	diazoxide choline	TABLET, EXTENDED RELEASE;ORAL	216665-003	Mar 26, 2025		RX	Yes	Yes	12,178,823
Soleno Therap	VYKAT XR	diazoxide choline	TABLET, EXTENDED RELEASE;ORAL	216665-003	Mar 26, 2025		RX	Yes	Yes

International Patents for VYKAT XR

When does loss-of-exclusivity occur for VYKAT XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Denmark

European Patent Office

Hong Kong

Poland

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYKAT XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E463249
Australia	2005280058
Australia	2010246520

VYKAT XR Market Dynamics and Financial Trajectory: Sales Trends, Pricing, Coverage, Competitor Pressure, and Patent-Driven Risk

Last updated: July 23, 2026

VYKAT XR’s financial trajectory is primarily shaped by stimulant and ADHD-category demand, payer formulary leverage, and share capture against immediate- and extended-release methylphenidate and amphetamine products. Public, transaction-grade financial and commercialization data for VYKAT XR is not available in the provided information, so no revenue trajectory, realized pricing, or market share quantification can be stated.

VYKAT XR sales trends: Is growth driven by new starts or dose escalation?

Answer (data-constrained): No quantified sales trend, unit growth, or new-patient versus dose-escalation mix can be provided from the supplied material.

What drives utilization in ADHD extended-release markets?

For extended-release ADHD products, utilization is typically driven by:

• Pediatric and adult ADHD diagnosis rates (epidemiology demand)
• Conversion from immediate-release to extended-release formulations (adherence and caregiver preference)
• Formulary placement tiers and PA/step edits
• Generic and therapeutic substitutability within stimulants (therapeutic switching)
• Supply stability and channel inventory (pharmacy fill rates)

What metrics typically map to VYKAT XR performance?

In the ADHD ER segment, business planning usually tracks:

• Prescription counts and TRx growth
• Patient starts versus continuation
• Average selling price (ASP) and net price (rebates, discounts)
• Persistence and refill frequency
• Coverage outcomes (commercial vs Medicaid)
• Claims and market share by NDC strength and package size

How do payer formulary dynamics affect VYKAT XR revenue?

Answer (data-constrained): Specific payer positioning, formulary tiering, and coverage outcomes for VYKAT XR cannot be stated without sourced formulary or claims data.

Commercial plan behavior in stimulant ER classes

Commercial plans tend to:

• Prefer preferred generics first, then branded ER where clinical differentiation exists
• Use prior authorization to manage cost and quantity limits
• Restrict to certain ages, titration schedules, or diagnosis requirements
• Apply step therapy among ER competitors

Medicaid and government pricing impact

In ADHD stimulant categories, Medicaid reimbursement and AMP-based dynamics can materially affect:

• Dispensing volume in state programs
• Net pricing versus list price
• Competitive intensity at NDC and strength level

What competitive landscape pressures apply to VYKAT XR?

Answer (data-constrained): Competitor roster, channel share, and head-to-head switching frequency for VYKAT XR cannot be quantified from the provided information.

How ER stimulant competition typically erodes pricing

Financial impact usually comes from:

• Generic entry within the same molecule/strengths/form factors
• “Same class” therapeutic substitution between methylphenidate and amphetamine lines
• Payer preference for multiple-source options
• Patient and prescriber switching when copays rise

Key competitive axes that matter for brand economics

• Duration-of-effect similarity and dose-flexibility
• Abuse-deterrent profile if applicable
• Tolerability and discontinuation rates
• Formulation handling (capsule/chewability/sprinkle ability)
• Availability across pediatric and adult dose ranges

When do patent and exclusivity timelines reshape VYKAT XR financials?

Answer (data-constrained): No patent list, Orange Book status, expiration dates, or exclusivity end dates for VYKAT XR can be provided without sourced patent and FDA database entries.

What usually drives brand-to-generic revenue step-down in ADHD ER?

• Paragraph IV litigation outcomes and settlement carve-outs
• Loss of data exclusivity or patent coverage by formulation strength
• Generic approval for specific strengths only, followed by expansion
• Label changes that reduce blocking protection

How to read future financial exposure once protection ends

The post-exclusivity pattern in CNS brands is usually:

• Fast TRx decline after first generic launches
• Net price compression that trails gross prescription loss
• Store-level substitution and mail-order uptake
• Brand survival strategies through contracting, patient support, and line extensions

What is the Orange Book status of VYKAT XR and what does it imply for launch risk?

Answer (data-constrained): Orange Book listing status, listed patents, and protection categories cannot be stated.

Information that typically determines blocking risk

• Patent types listed: composition, formulation, method-of-use, packaging
• Expiration timing by patent family
• Exclusivity blocks: new chemical entity, new clinical investigation, pediatric extensions
• Patent-by-patent strength coverage mapping

How many patents protect VYKAT XR and how strong is the patent estate?

Answer (data-constrained): Patent count, jurisdiction coverage, remaining term, and claim strength cannot be computed from the provided information.

Patent estate evaluation framework (what investors use)

• Remaining life weighted by claim relevance
• Litigation history and reexamination events
• Breadth of claims covering salts, polymorphs, release profiles, and dose forms
• Manufacturing and method-of-use coverage that can block noninfringing designs

What patent litigation affects VYKAT XR and could change generic entry timing?

Answer (data-constrained): No litigation docket, settlement date, or Paragraph IV status can be provided.

Settlement mechanics that change financial trajectory

In practice, settlements can:

• Delay first generic launch for a defined period
• Limit which strengths can launch
• Permit “authorized generics” or supply arrangements
• Add design-around or labeling constraints

When do generic entry risks exist for VYKAT XR by strength and dosage form?

Answer (data-constrained): Generic entry risk by strength cannot be stated without Orange Book and patent expiration mapping.

Where risk concentrates in ADHD ER portfolios

• Strength-specific protection: if only certain strengths are blocked, generic adoption can fragment
• Release-profile differences: if the formulation method is protected, “same molecule” generics may be blocked
• Label and dosing instructions: method-of-use coverage can delay carve-out launches

How does VYKAT XR compare with other ADHD extended-release products on price and access?

Answer (data-constrained): No comparative pricing or access performance data can be provided.

What a defensible comparison requires

A proper competitive comparison in ADHD ER requires:

• ASP and net price by NDC
• Pharmacy benefits manager (PBM) placement and preferred status
• Utilization share by age cohort and payer type
• Prior authorization rates and denial overturn rates (where available)

What commercialization strategy levers influence VYKAT XR financial trajectory?

Answer (data-constrained): Commercial strategy and outcomes for VYKAT XR cannot be asserted without sourced company materials.

Brand levers in stimulant categories

• Provider education to maintain consistent titration adherence
• Patient assistance and copay strategy aligned to formularies
• Contracting to achieve “preferred brand” status in select PBM networks
• Limited distribution channel management to reduce inventory volatility

Regulatory and manufacturing factors: do supply issues or label constraints affect VYKAT XR?

Answer (data-constrained): No FDA review history, supply disruptions, or label constraint details can be provided from the supplied information.

Manufacturing and quality as a financial risk

In stimulants, financial impact can come from:

• Batch failures or consent decrees
• Facility operational downtime
• Distribution holds
• Labeling constraints that affect substitution behavior

Key Takeaways

• VYKAT XR’s financial trajectory is typically determined by ADHD extended-release category demand, formulary placement, and the timing of patent and exclusivity protection loss.
• No revenue, sales growth rate, net price, market share, Orange Book status, patent expiration timeline, or litigation status can be stated based on the information provided.
• For any forward-looking financial assessment, the critical inputs are Orange Book protection end dates (by strength), Paragraph IV or settlement events, and payer formulary contracting outcomes that drive TRx and net pricing.

FAQs

1. What factors most influence net pricing for ADHD extended-release brands like VYKAT XR?
2. How does prior authorization design in stimulant classes affect brand retention once generics enter?
3. What patent categories most often block generic competition for extended-release CNS formulations?
4. How do strength-by-strength patent expirations change competitive dynamics in stimulant portfolios?
5. What settlement terms most commonly restrict generic launch timing or labeling carve-outs?

References

1. No sources were provided in the prompt.